299 related articles for article (PubMed ID: 28838273)
1. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
[TBL] [Abstract][Full Text] [Related]
2. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
Keil R; Wasserbauer M; Zádorová Z; Hajer J; Drastich P; Wohl P; Beneš M; Bojková M; Svoboda P; Konečný M; Falt P; Vaňásek T; Pešta M; Pešek F; Bouchner L; Koželuhová J; Novotný A; Bartůsková L; Špičák J
Scand J Gastroenterol; 2016 Sep; 51(9):1062-8. PubMed ID: 27002981
[TBL] [Abstract][Full Text] [Related]
3. Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease.
Kim ES; Choi S; Choe BH; Park S; Lee YJ; Sohn SJ; Kim SC; Kang KS; Lee K; Shim JO; Kim YB; Hong SJ; Lee YM; Kim HJ; Choi SY; Kim JY; Lee Y; Park JS; Kim JY; Yi DY; Lee JH; Choi KH; Jang HJ; Jeong IS; Kang B
Front Immunol; 2024; 15():1284181. PubMed ID: 38455036
[TBL] [Abstract][Full Text] [Related]
4. Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies.
Takeuchi T; Nishikawa K; Yamada F; Morita A; Ohtsuki M; Suzuki Y; Watanabe M; Yamanaka H; Hibi T
Drug Saf; 2023 Oct; 46(10):991-1005. PubMed ID: 37700154
[TBL] [Abstract][Full Text] [Related]
5. CT-P13: design, development, and place in therapy.
Gabbani T; Deiana S; Annese V
Drug Des Devel Ther; 2017; 11():1653-1661. PubMed ID: 28652703
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study.
Buisson A; Nachury M; Reymond M; Yzet C; Wils P; Payen L; Laugie M; Manlay L; Mathieu N; Pereira B; Fumery M
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2338-2346.e3. PubMed ID: 35987302
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Pica R; Pranzo G; Rodino' S; Scarcelli A; Zampaletta C; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Faggiani R; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Picchio M; Sacco R; Sebkova L; Serio M; Napolitano D; Pugliese D; Scaldaferri F; Schiavoni E; Turchini L; Armuzzi A; Elisei W; Maconi G; Papa A
Inflamm Bowel Dis; 2023 Mar; 29(3):376-383. PubMed ID: 35579320
[TBL] [Abstract][Full Text] [Related]
8. Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study.
Hanzel J; Jansen JM; Ter Steege RWF; Gecse KB; D'Haens GR
Inflamm Bowel Dis; 2022 Mar; 28(4):495-501. PubMed ID: 34013959
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and cost savings of a nonmedical switch to a biosimilar in children/young adults with inflammatory bowel disease.
McNicol M; Abdel-Rasoul M; McClinchie MG; Morris GA; Boyle B; Dotson JL; Michel HK; Maltz RM
J Pediatr Gastroenterol Nutr; 2024 Mar; 78(3):644-652. PubMed ID: 38334232
[TBL] [Abstract][Full Text] [Related]
10. Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD).
Bokemeyer B; Hlavaty T; Allez M; Selema P; Moosavi S; Cadatal MJ; Fowler H; Mueller M; Liau KF; Gisbert JP
Expert Opin Biol Ther; 2023; 23(8):791-800. PubMed ID: 37038897
[TBL] [Abstract][Full Text] [Related]
11. Factors that influence infliximab biosimilar trough levels in the pediatric inflammatory bowel disease population.
Dipasquale V; Alibrandi A; Pellegrino S; Ramistella V; Romano C
Expert Rev Clin Immunol; 2024 Feb; 20(2):237-244. PubMed ID: 37962991
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn's disease.
Roblin X; Veyrard P; Bastide L; Berger AE; Barrau M; Paucelle AS; Waeckel L; Kwiatek S; Flourie B; Nancey S; Paul S
Aliment Pharmacol Ther; 2022 Jul; 56(1):77-83. PubMed ID: 35229331
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study.
Serrano Díaz L; Iniesta Navalón C; Gómez Espín R; Nicolás De Prado I; Bernal Morell E; Rentero Redondo L
Gastroenterol Hepatol; 2024; 47(6):553-561. PubMed ID: 37597745
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study.
Wetwittayakhlang P; Karkout K; Wongcha-Um A; Tselekouni P; Al-Jabri R; Afif W; Wild G; Bitton A; Bessissow T; Lakatos PL
Dig Liver Dis; 2024 Jan; 56(1):35-42. PubMed ID: 37419726
[TBL] [Abstract][Full Text] [Related]
15. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.
Ljung T; Karlén P; Schmidt D; Hellström PM; Lapidus A; Janczewska I; Sjöqvist U; Löfberg R
Gut; 2004 Jun; 53(6):849-53. PubMed ID: 15138212
[TBL] [Abstract][Full Text] [Related]
16. Direct transition from rapid-infusion originator to rapid-infusion biosimilar tumor necrosis factor inhibitor in children with inflammatory bowel disease: A case series.
Rosenthal B; Aulakh S; Patel PV; Wong JT; Ali S
Am J Health Syst Pharm; 2024 Jan; 81(2):61-65. PubMed ID: 37773728
[TBL] [Abstract][Full Text] [Related]
17. Similar Growth Outcomes in Children with Inflammatory Bowel Disease Initiated on Infliximab Originator or Biosimilar.
McClinchie MG; Lakhani A; Abdel-Rasoul M; McNicol M; Shkhkhalil AK; Boyle BB; Maltz RM
J Pediatr Gastroenterol Nutr; 2023 Oct; 77(4):499-504. PubMed ID: 37439588
[TBL] [Abstract][Full Text] [Related]
18. Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study.
Massimi D; Barberio B; Bertani L; Costa F; Ferronato A; Facchin S; Cardin R; Cingolani L; Casadei C; D'Incà R; Zingone F; Savarino EV
Therap Adv Gastroenterol; 2021; 14():17562848211023384. PubMed ID: 34249147
[TBL] [Abstract][Full Text] [Related]
19. Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
Vuijk SA; Jongsma MME; Hoeven BM; Cozijnsen MA; van Pieterson M; de Meij TGJ; Norbruis OF; Groeneweg M; Wolters VM; van Wering H; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg S; Rizopoulos D; Poley MJ; Escher JC; de Ridder L
Aliment Pharmacol Ther; 2024 Jun; 59(12):1510-1520. PubMed ID: 38644588
[TBL] [Abstract][Full Text] [Related]
20. Effects of prednisolone tapering on effectiveness of infliximab in patients with ulcerative colitis: data from a retrospective cohort.
Ovesen PD; Attauabi M; Ilvemark JFKF; Wewer MD; Warren DJ; Burisch J; Klaasen RA; Bolstad N; Steenholdt C; Seidelin JB
BMJ Open Gastroenterol; 2024 May; 11(1):. PubMed ID: 38719549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
